RNA Drug Delivery System siRNA / ASO / PMO Conjugation Enhanced Delivery Efficiency
At BOC Sciences, we specialize in advanced antibody-RNA conjugation (AOC) technology, integrating precise antibody targeting with the functional power of RNA therapeutics to overcome delivery barriers in modern drug development. By combining state-of-the-art bioconjugation chemistry, proprietary linker design, and deep expertise in antibody and oligonucleotide engineering, we create high-quality conjugates that enable selective delivery of siRNA, ASO, or PMO payloads to specific tissues or cells. Our platform supports every stage—from discovery and feasibility testing to process scale-up and GMP-ready production—helping researchers, biotech innovators, and pharmaceutical companies accelerate the translation of next-generation RNA-based therapies into clinical reality.
Traditional RNA therapeutics often struggle with instability, poor biodistribution, and limited cell penetration. Our antibody-RNA conjugate platform solves these challenges by:
Targeted delivery - directing RNA payloads to disease-relevant tissues or receptors with antibody precision.
Enhanced cellular uptake - improving internalization and endosomal escape efficiency.
Reduced off-target toxicity - minimizing unwanted systemic exposure and side effects.
Improved therapeutic performance - increasing RNA potency and durability in vivo.
Streamlined development workflow - integrating conjugation, analytics, and production in a single pipeline.
We provide a comprehensive suite of custom antibody-RNA conjugation services, including:
Antibody-Oligonucleotide Conjugation
RNA Payload Design and Synthesis
Linker and Chemistry Optimization
Analytical and Characterization Services
Scale-Up and GMP Manufacturing Support
In Vitro and In Vivo EvaluationOur antibody-RNA conjugation service process is designed for efficiency, transparency, and scientific rigor. From concept to delivery, each stage is managed by specialized teams to ensure seamless execution and high-quality outcomes.
We begin with an in-depth discussion of your project objectives, target tissue, and RNA modality. Our scientific team proposes optimal antibody targets, linker strategies, and conjugation chemistry.
We evaluate technical feasibility, provide a tailored work plan, and define deliverables, timeline, and cost estimation.
Our experts perform small-scale conjugation under optimized conditions, establishing key parameters such as DAR, purity, and yield.
Each conjugate is rigorously analyzed by LC-MS, HPLC, and stability testing to confirm structural integrity and performance.
Once the conjugation route is validated, we provide process development and scale-up support, ensuring readiness for cGMP production.
Final reports include complete QC data, certificates of analysis, and method documentation. Continuous technical consultation is available for downstream applications or regulatory filing.
Our team combines decades of experience in antibody engineering, nucleic acid chemistry, and linker design. This multidisciplinary knowledge ensures precise, reproducible conjugation for diverse RNA formats-including siRNA, ASO, and PMO.
We offer both site-specific and random coupling methods, using advanced chemistries such as click conjugation and thiol-maleimide reactions. Each project is tailored to your payload, target, and desired release mechanism.
From RNA synthesis to analytical validation and manufacturing, our integrated platform minimizes transfer risk and accelerates your development timeline-reducing complexity and cost.
Every conjugate undergoes comprehensive analytical verification. We provide quantitative DAR analysis, purity profiling, and stability data to meet publication, preclinical, or regulatory requirements.
We can deliver milligram-scale research samples or scale up to gram-level batches suitable for IND-enabling studies. GMP-readiness is built into every workflow, supporting smooth tech transfer to manufacturing.
Each client is paired with a dedicated project manager and scientific liaison. We provide transparent progress updates, milestone tracking, and rapid communication throughout the engagement.
Our antibody-RNA conjugation technology unlocks powerful possibilities across multiple therapeutic and research domains. Below are the key application areas where AOC technology delivers transformative impact:
Enables targeted delivery of siRNA or PMO to skeletal muscle cells for treating diseases such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1).
Facilitates efficient transport of RNA therapeutics across the blood-brain barrier via receptor-mediated antibody targeting, expanding treatment options for neurodegenerative disorders.
Combines tumor-specific antibodies with RNA payloads to silence oncogenes or modulate immune checkpoints-enhancing precision and reducing systemic toxicity.
Offers a customizable delivery platform for gene silencing or exon-skipping therapies targeting rare genetic mutations at the RNA level.
Delivers antisense oligonucleotides or siRNA precisely to hepatocytes or endothelial cells, improving metabolic regulation and minimizing off-target effects.
Enables development of antibody-guided RNA therapeutics for preclinical testing, allowing rapid evaluation of new disease targets and delivery systems.
Antibody-RNA conjugation (AOC) is a bioconjugation technique that links therapeutic RNA molecules—such as siRNA, ASO, or PMO—to antibodies for targeted delivery to specific cells or tissues. This approach combines the selectivity of antibodies with the gene-regulating capability of RNA therapeutics.
We support a wide range of RNA modalities, including siRNA, antisense oligonucleotides (ASO), phosphorodiamidate morpholino oligomers (PMO), and other modified oligonucleotides designed for enhanced stability and efficacy.
Our platform supports various conjugation methods, such as thiol-maleimide coupling, click chemistry, amide bond formation, and cleavable linker strategies optimized for controlled release and biological compatibility.
Absolutely. Clients may supply their own antibody, oligonucleotide, or sequence design. We also provide guidance on optimization and synthesis when required.
Simply contact us with your target indication, antibody or RNA sequence (if available), and desired specifications. Our scientific team will review your request, provide a feasibility assessment, and design a customized proposal within a few business days.
Partner with BOC Sciences, your trusted expert in antibody-RNA conjugation services, to design, develop, and scale precise AOC solutions that deliver real biological impact. Whether you're exploring early proof-of-concept studies or preparing for drug discovery development, our team is here to turn your innovation into measurable results. Contact us today to discuss your project or request a customized quotation - let's build the future of targeted RNA delivery together.
